{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "Amount",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "pubchem:11006",
      "entity_text" : "CNS",
      "entity_type" : "simple_chemical"
    },
    "hypothesis_information" : false,
    "context" : {
      "Species" : [ "taxonomy:9606" ],
      "TissueType" : [ "tissuelist:TS-0150" ],
      "Cellular_component" : [ "go:GO:0031982" ]
    }
  },
  "verbose_text" : "For instance, CSF LRRK2 concentrations could serve as a patient enrichment tool and/or a pharmacodynamic endpoint if a therapy aims to modulate aberrant CNS levels, e.g., with an antisense oligonucleotide (ASO) or gene therapy approach.",
  "reading_complete" : "2020-08-05T19:58:52Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-05T19:57:38Z",
  "trigger" : "levels",
  "evidence" : [ "CNS levels" ],
  "pmc_id" : "7262382",
  "score" : 0
}